Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Authors
Keywords
Lurbinectedin, Ovarian cancer, Platinum-resistant, Phase III study
Journal
GYNECOLOGIC ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-09-12
DOI
10.1016/j.ygyno.2021.08.032
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
- (2020) José Trigo et al. LANCET ONCOLOGY
- Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
- (2018) Cristina Cruz et al. JOURNAL OF CLINICAL ONCOLOGY
- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
- (2016) G. Santamaria Nunez et al. MOLECULAR CANCER THERAPEUTICS
- Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
- (2016) Michelle Lima et al. Oncotarget
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) J. A. Ledermann et al. ANNALS OF ONCOLOGY
- Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
- (2012) A. Vidal et al. CLINICAL CANCER RESEARCH
- Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
- (2012) Nicoletta Colombo et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
- (2011) D. G. Soares et al. MOLECULAR CANCER THERAPEUTICS
- PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
- (2010) JFM Leal et al. BRITISH JOURNAL OF PHARMACOLOGY
- Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
- (2010) Ignace Vergote et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2010) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
- (2009) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now